Brought to you by 
Artax Biopharma closes $10mm Series B round; Later completes extension
04 Jun 2020
Executive Summary
Artax Biopharma Inc. (autoimmune disease therapies) raised $10mm through its Series B round. Henri Termeer and Advent Life Sciences led (and both take board seats), and were joined by AM Pappas and existing backers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Artax Biopharma closes $10mm Series B round; Later completes extension
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice